Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Catabasis names VP, development

This article was originally published in Scrip

Executive Summary

Catabasis Pharmaceuticals, which develops drugs for severe lipid disorders and rare diseases, has named Dr Angelika Fretzen vice-president of development. Prior to joining Catabasis Dr Fretzen was vice-president of pharmaceutical chemistry and development at Ironwood Pharmaceuticals. She has been responsible for discovery and development programs for small molecules and peptides in a variety of different disease areas and prior to joining Ironwood Dr Fretzen was an Alexander von Humboldt Fellow in the department of chemistry and chemical biology at Harvard University.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts